Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | AHCY | P23526 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385752 | 1.00 | CYP3A4 (0.73) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL29437221 | 1.00 | CYP3A4 (0.73) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL10047654 | 0.91 | CYP3A4 (0.64) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL14669069 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL2556627 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL2556635 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL2928584 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL12354858 | 0.90 | CYP3A4 (0.62) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL9190527 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY | |
| SCHEMBL384145 | 0.90 | CYP3A4 (0.72) | CYP3A4FGFR1SLC22A6ADORA2AAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022013813-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR USE IN TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | UNIVERSITÀ DEGLI STUDI DI PADOVA (IT) | 2022-01-20 | — | — | WO | claimed |
| US-20160000937-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS, INC. | 2016-01-07 | — | — | US | claimed |
| US-20140065072-A1 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy | ALT SOLUTIONS INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-8580753-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20120107863-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-8097595-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS, INC. (US) | 2012-01-17 | — | — | US | claimed |
| JP-2012500104-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2320991-A2 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | Third Rock Ventures (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010022252-A2 | DEVICE AND METHOD FOR DRUG EVALUATION AND LOCAL TREATMENT | THIRD ROCK VENTURES (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1165570-B1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2006-08-23 | — | — | EP | claimed |
| US-6964968-B2 | Method for the treatment or prevention of viral infection using nucleoside analogues | SHIRE BIOCHEM, INC. (CA) | 2005-11-15 | — | — | US | claimed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | claimed |
| US-20250352777-A1 | SUBMUCOSAL BIORESORBABLE DRUG ELUTING PLATFORM | INTERSECT ENT INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12403291-B2 | Submucosal bioresorbable drug eluting platform | INTERSECT ENT, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12350274-B2 | Nucleotide analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3791826-B1 | SELF-EXPANDING DEVICES | INTERSECT ENT INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20050180925-A1 | powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; comprise an antifungal agent, antibiotic or antiviral agent; fungus-induced rhinosinusitis | DEY, L.P. | 2005-08-18 | — | — | US | disclosed |
| US-20040209852-A1 | Fluticasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; comprise an antifungal agent, antibiotic or antiviral agent; fungus-induced rhinosinusitis | MYLAN SPECIALTY L.P. | 2004-10-21 | — | — | US | disclosed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | disclosed |
| US-5874577-A | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof | MEDICHEM RESEARCH, INC. (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350274-B2 | Nucleotide analogs | NUDT1, DUT, DPYD | CYP3A4 3875/4885FGFR1 3575/4885SLC22A6 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.